Mast Therapeutics To Host Third Quarter 2016 Financial Results And Business Update Conference Call
Dienstag, 01.11.2016 21:10 von PR Newswire
PR Newswire
SAN DIEGO, Nov. 1, 2016
SAN DIEGO, Nov. 1, 2016 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that the Company will release its third quarter 2016 financial results on Tuesday, November 8, 2016. The Company will also host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss third quarter financial results and provide a general business update.
Interested parties may access the conference call by dialing (855) 239-3120 from the U.S. and (412) 542-4127 from outside the U.S. and should request the Mast Therapeutics, Inc. Third Quarter 2016 Conference Call. A live webcast of the conference call will be available online from the Investors section of Mast's website at http://www.masttherapeutics.com/investors/events/. Replays of the webcast will be available on the Company's website for 30 days and a telephone replay will be available through November 15, 2016 by dialing (877) 344-7529 from the U.S. and (412) 317-0088 from outside the U.S. and entering replay access code 10096120.
About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California. The Company has two clinical-stage investigational new drugs, AIR001 and vepoloxamer. AIR001, a sodium nitrite solution for intermittent inhalation via nebulization, is in Phase 2 clinical development for the treatment of heart failure with preserved ejection fraction (HFpEF). More information can be found on the Company's web site at www.masttherapeutics.com. Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.
Logo - http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mast-therapeutics-to-host-third-quarter-2016-financial-results-and-business-update-conference-call-300355318.html
SOURCE Mast Therapeutics, Inc.